Hi all:
I started work in Lipid-Base dosage form development in 2007 where I supported a development candidate for Penwest Pharmaceuticals. This molecule was taken from pre-clinical through Phase 2 and was scheduled for Phase 3 development until the program was cancelled after the acquisition of Penwest.
I continued work in this field at Capsugel developing and characterizing lipid-based dosage form development for poorly soluble nutraceuticals.
I also set up the Gattefossé Application lab in Paramus, NJ and continued work in the field.
If you need help with member recruitment or scheduling of meetings, please feel free to contact me.
@Masumi Dave , I am available to lend support.
Kind regards,
Jason LePree